Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
PAVmed Inc. Series Z Warrant (PAVMZ)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: PAVMZ (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -58.73% | Avg. Invested days 15 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size ETF | Market Capitalization 0 USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) 20502 | Beta 1.14 | 52 Weeks Range 0.00 - 0.07 | Updated Date 03/30/2025 |
52 Weeks Range 0.00 - 0.07 | Updated Date 03/30/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) - |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 1328.58% | Operating Margin (TTM) -51870% |
Management Effectiveness
Return on Assets (TTM) -87.19% | Return on Equity (TTM) -1358.06% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value - | Price to Sales(TTM) - |
Enterprise Value - | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding - | Shares Floating 12741800 |
Shares Outstanding - | Shares Floating 12741800 | ||
Percent Insiders - | Percent Institutions - |
Analyst Ratings
Rating - | Target Price - | Buy - | Strong Buy - |
Buy - | Strong Buy - | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
PAVmed Inc. Series Z Warrant
Company Overview
History and Background
PAVmed Inc. is a multi-product, commercial-stage medical device company. The Series Z Warrant represents the right to purchase shares of PAVmed's common stock under specific conditions. The company was founded in 2014. Milestones include the development and commercialization of its various medical devices and financings.
Core Business Areas
- Medical Devices: Development and commercialization of innovative medical devices across multiple therapeutic areas.
Leadership and Structure
Dr. Lishan Aklog is the Chairman and CEO. The company has a typical corporate structure with a board of directors and executive management team.
Top Products and Market Share
Key Offerings
- CarpX: Minimally invasive device for carpal tunnel syndrome. Limited market share data available; faces competition from traditional open surgery and other minimally invasive techniques. Competitors include Stryker, CONMED, and DePuy Synthes.
- EsoGuard/EsoCheck: Esophageal cell collection device and DNA test for Barrett's esophagus. Increasing adoption; competes with traditional endoscopy. Competitors include Exact Sciences (Cologuard, biomarkers). Limited revenue data available.
- PortIO: Implantable intraosseous vascular access system. Early stage development; potential to disrupt traditional IV access. Competitors include Becton Dickinson and Teleflex.
Market Dynamics
Industry Overview
The medical device industry is highly competitive and regulated, characterized by innovation, technological advancements, and evolving healthcare needs.
Positioning
PAVmed aims to disrupt established medical procedures with its innovative and less invasive devices.
Total Addressable Market (TAM)
Total TAM across their product portfolio is estimated at several billion USD. PAVmed is focused on penetrating specific segments of the TAM with innovative solutions.
Upturn SWOT Analysis
Strengths
- Innovative product pipeline
- Proprietary technology
- Experienced management team
Weaknesses
- Limited financial resources
- Dependence on regulatory approvals
- Commercialization challenges
Opportunities
- Expanding market for minimally invasive procedures
- Strategic partnerships
- Acquisition targets
Threats
- Competition from larger medical device companies
- Reimbursement challenges
- Technological obsolescence
Competitors and Market Share
Key Competitors
- Stryker (SYK)
- Becton Dickinson (BDX)
- CONMED Corporation (CNMD)
Competitive Landscape
PAVmed competes with larger, more established medical device companies. Its competitive advantage lies in its innovative technologies and minimally invasive approaches, however, these need to be converted to commercial success.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Growth dependent on successful commercialization and regulatory approvals.
Future Projections: Future growth reliant on successful product launches and market penetration.
Recent Initiatives: Focus on commercializing EsoGuard/EsoCheck and advancing other pipeline products.
Summary
PAVmed is a promising but risky medical device company with innovative products and a seasoned leadership team. Its future hinges on successful product commercialization and regulatory approvals. The company needs to carefully manage its finances and navigate a competitive landscape. PAVmed operates in a high-growth market with unmet medical needs, but faces significant competition.
Similar Companies
Sources and Disclaimers
Data Sources:
- PAVmed Inc. SEC Filings
- Industry Reports
- Analyst Estimates
Disclaimers:
This analysis is for informational purposes only and does not constitute financial advice. Market share data are estimates and may not be precise. Financial data should be verified from official company filings.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About PAVmed Inc. Series Z Warrant
Exchange NASDAQ | Headquaters New York, NY, United States | ||
IPO Launch date 2018-04-10 | Chairman & CEO Dr. Lishan Aklog M.D. | ||
Sector Healthcare | Industry Medical Devices | Full time employees 39 | Website https://www.pavmed.com |
Full time employees 39 | Website https://www.pavmed.com | ||
PAVmed Inc. focuses on acquiring, developing, and commercializing novel products that target unmet needs in the United States. The company's lead products include CarpX, a patented, single-use, disposable, and minimally invasive surgical device for use in the treatment of carpal tunnel syndrome; EsoCheck Esophageal Cell Collection Device, which consists of diagnostic test that serves as a testing tool for preventing esophageal adenocarcinoma deaths, through early detection of esophageal precancer in at-risk gastroesophageal reflux disease, including chronic heartburn and acid reflux or simply reflux in patients; and EsoGuard, a bisulfite-converted next-generation sequencing DNA assay performed on surface esophageal cells collected with EsoCheck. Its product pipeline also comprises EsoCure EsoCure Esophageal Ablation Device for treating dysplastic BE; PortIO, an implantable intraosseous vascular access device; and Veris cancer care platform. The company was formerly known as PAXmed Inc. and changed its name to PAVmed Inc. in April 2015. PAVmed Inc. was incorporated in 2014 and is headquartered in New York, New York.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.